Skip Navigation


Rheumatology Advance Access originally published online on May 30, 2006
Rheumatology 2006 45(8):1047-1048; doi:10.1093/rheumatology/kel172
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/8/1047    most recent
kel172v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wilkinson, N. M. R.
Right arrow Articles by Cabral, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilkinson, N. M. R.
Right arrow Articles by Cabral, D. A.
Related Collections
Right arrow Vasculitis
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTER TO THE EDITOR

Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis

N. M. R. Wilkinson, E. Erendzhinova1, A. Zeft2 and D. A. Cabral1

Nuffield Orthopaedic Centre, Oxford, UK, 1 British Columbia Children's Hospital, Vancouver, Canada and 2 Seattle Children's Hospital, Washington, USA

Correspondence to: Dr Nick Wilkinson, Nuffield Orthopaedic Centre, Windmill Road, Oxford OX4 7LD, UK. E-mail: nick.wilkinson@noc.anglox.nhs.uk

The first 10% of the full text of this article appears below.

SIR, This is the first report of infliximab (IFX) use in children with severe, refractory Wegener's granulomatosis (WG), a necrotizing vasculitis of the upper respiratory tract and kidneys. The rationale for tumour necrosis factor {alpha} (TNF{alpha}) blockade includes a key role of TNF{alpha} in granuloma formation and maintenance of vasculitis in WG [1–6]. In addition, IFX has been shown to be effective in the management of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?